Mirum PharmaceuticalsMIRM
Recorded

Mirum Pharmaceuticals 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Welcome everyone to the next session here. Happy to be joined by Mirum Pharmaceuticals. We have CFO Eric Bjerkholt and Andrew McKibben, SVP Strategic Finance and IR. A lot going on at Mirum, so we can jump right in. Maybe, Eric or Andrew, if you just want to kind of give a brief overview of recent quarter. You've had a lot of data going on, so maybe just kind of set the stage, and then we can dive in.

Eric BjerkholtCFO

Sure. First, thank you for having us. Thank you to Stifel for organizing the conference. We will be making forward-looking statements, so please refer to risk factors in our SEC filings. We now have four approved medicines. We're experiencing really rapid revenue growth. We've guided to revenues of $715 million-$720 million for this year, with strong momentum going into next year. We see growth from all our medicines, and next year we expect significant contributions from ATEBRIOZ in FOP, which was very recently approved. We've guided to being cash flow positive in 2027. We were cash flow positive last year, cash flow positive first half of this year, but second half of this year, we have a heavy R&D lift in part with significant investments in CMC for the expected filing of brelovitug next year, as well as for volixibat.

Eric BjerkholtCFO

Sets us up really well for continued growth and good financial performance next year.

Speaker

Great. Makes sense. Maybe we can just start off with some of the pipeline assets. Obviously, you guys have had kind of a lot of updates recently. I think PSC naturally remains kind of a focus for folks, so maybe it'd be helpful just to kind of lay out sort of some of the context there and sort of your kind of continued perspectives on sort of the path forward there.

Eric BjerkholtCFO

It's Andrew's favorite topic. Yeah.

Andrew McKibbenSVP of Strategic Finance and Investor Relations

Yeah, you know, it's funny, no one asks us about this.

Andrew McKibbenSVP of Strategic Finance and Investor Relations

Yeah. Thank you. Yeah, just a little bit of context.

Andrew McKibbenSVP of Strategic Finance and Investor Relations

We're planning to file in the first half of next year. We received feedback in July from the FDA at our pre-NDA meeting. They recommended a phase III, but noted that we could file at our discretion. Based on our understanding of where that review team was, and it was a new review team, we felt that it would behoove us to take some turns to interact with them with our breakthrough designation before we put that submission in, just to bring them closer to the dataset. There was no specific issue that they were pointing at behind their recommendation or specific recommendations around what a phase III should look like, which tells us that there was just lack of familiarity with the program and a review team that was a bit newer to the program.

Andrew McKibbenSVP of Strategic Finance and Investor Relations

Taking a couple iterations to interact and get them closer to what we've done, it's a very robust data package, before we put that submission in, we thought would be prudent. That's where we are. If anything changes in this kind of back and forth with them between now and submission that's material, that changes our plans, we would certainly update you. But right now, everything's on track.

Speaker

Sounds good. You may not be able to answer this, but want to ask it. Just in terms of, do you think there is like sort of an alignment that is going to happen before you submit, or is it going to be more like we will just have to kind of see throughout the review?

Andrew McKibbenSVP of Strategic Finance and Investor Relations

Just curious if you think there is going to- The latter is a win, right?

Andrew McKibbenSVP of Strategic Finance and Investor Relations

Yeah. I mean, rarely do I would not expect them to say, "I am sorry, we love you, please submit.

Andrew McKibbenSVP of Strategic Finance and Investor Relations

Yeah. Like, that just does not That is not a thing the FDA does.

Andrew McKibbenSVP of Strategic Finance and Investor Relations

It is usually moving the conversation to a review issue, which is where we think a lot of this should be.

Speaker

Yeah. Makes sense. At AASLD this past weekend, you guys shared some additional data for PSC. Maybe just kind of recap that briefly and the importance of that data and rounding out the broader clinical profile for volixibat.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day